Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies

A. Diaz Miqueli, J. Rolff, M. Lemm, I. Fichtner, R. Perez, E. Montero

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

74 Citas (Scopus)


As epidermal growth factor receptor (EGFR) has been reported to be a radiation response modulator, HER inhibitors are regarded to act as potential radiosensitisers. Our study examined the role of nimotuzumab and cetuximab both, the two monoclonal antibodies (mAbs) to EGFR, as radiosensitisers in a murine glioma model in vivo. Co-administration of both the antibodies with radiation increased the radiosensitivity of U87MG, resulting in a significant delay of subcutaneous (s.c.) tumour growth. Furthermore, the addition of antibodies to the radiation decreased brain tumour sizes and is inhibited by 40-80% the increased tumour cell invasion provoked by radiotherapy, although promoted tumour cell apoptosis. Whereas nimotuzumab led to a reduction in the size of tumour blood vessels and proliferating cells in s.c. tumours, cetuximab had no significant antiangiogenic nor antiproliferative activity. In contrast, cetuximab induced a more marked inhibition of EGFR downstream signalling compared with nimotuzumab. Moreover, both antibodies reduced the total number of radioresistant CD133+ cancer stem cells (CSCs). These results were encouraging, and showed the superiority of combined treatment of mAbs to EGFR and radiation over each single therapy against glioblastoma multiforme (GBM), confirming the role of these drugs as radiosensitisers in human GBM. In addition, we first showed the ability of mAb specifics against EGFR to target radioresistant glioma CSC, supporting the potential use in patients.

Idioma originalInglés
Páginas (desde-hasta)950-958
Número de páginas9
PublicaciónBritish Journal of Cancer
EstadoPublicada - 24 mar. 2009
Publicado de forma externa


Profundice en los temas de investigación de 'Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies'. En conjunto forman una huella única.

Citar esto